Follicular Lymphoma Archives

Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma

By

March 28, 2023

Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.

Lymphoma

Ultra-Low-Dose Radiation Appears Effective in Orbital Indolent B-Cell Lymphoma

By

Leah Lawrence

November 2, 2022

Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.

Lymphoma

Mosunetuzumab Demonstrates Activity in Relapsed/Refractory Follicular Lymphoma

By

Andrea S. Blevins Primeau, PhD, MBA

August 4, 2022

Mosunetuzumab produced an objective response rate of 80%.

Lymphoma

Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma

By

Vicki Moore, PhD

July 15, 2022

Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.

Lymphoma

Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma

By

Vicki Moore, PhD

July 5, 2022

Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.

Lymphoma

FDA Withdraws Approval of Ukoniq Over Safety Concerns

By

Brian Park, PharmD

June 8, 2022

Updated findings from the UNITY-CLL trial continue to show a possible increased risk of death among patients who received Ukoniq.

Lymphoma

GALEN Combination Yields Promising Results in Untreated Follicular Lymphoma

By

Jonathan Goodman, MPhil

June 2, 2022

Researchers sought to determine whether the GALEN regimen would yield favorable clinical outcomes in patients with previously untreated follicular lymphoma.